Combination therapy for hypertension in patients with CKD: a subanalysis of the Combination Therapy of Hypertension to Prevent Cardiovascular Events trial

Estudios importantes sobre hipertension arterial de Cuba y el mundo

Combination therapy for hypertension in patients with CKD: a subanalysis of the Combination Therapy of Hypertension to Prevent Cardiovascular Events trial

Por: Hiromi Rakugi, Toshio Ogihara, Seiji Umemoto, Masunori Matsuzaki, Hiroaki Matsuoka, Kazuyuki Shimada, Jitsuo Higaki, Sadayoshi Ito, Akira Kamiya, Hiromichi Suzuki, Yasuo Ohashi, Kazuaki Shimamoto y Takao Saruta for the Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial Group.  Hypertension Research (2013) 36, 947–958.

Chronic kidney disease (CKD) and hypertension are closely related in a vicious cycle; thus, blood pressure (BP) control is extremely important for patients with CKD. Both CKD and hypertension are risk factors for cardiovascular events; therefore, the aim of BP control in CKD is to inhibit the progression of CKD, delay worsening of the disease to end-stage kidney disease and inhibit the occurrence of cardiovascular events.
It is well recognized that antihypertensive therapy inhibits cardiovascular events regardless of the presence or absence of CKD. Reducing BP is the most important intervention to delay worsening of CKD as well; it has been shown that renin-angiotensin system blockers have an added effect in patients with advanced nephropathy and albuminuria of >33.9 mg mmol.